INTRODUCTION: Cardiac excitation-contraction (E-C) coupling refers to a cascade of Ca

2+
-mediated events whereby membrane depolarization leads to cell contraction. At the subcellular level, E-C coupling occurs within a microdomain of the cardiomyocyte, termed the cardiac dyad. In various forms of heart disease, such as pathological hypertrophy and heart failure, the E-C coupling process is abnormal, in part because of ultrastructural remodeling. Abnormal Ca 2+ homeostasis (as a result of failed E-C coupling) triggers maladaptive remodeling at the transcriptional level, contributing to pathological myocardial remodeling, hypertrophy, and heart failure. However, it remains unclear whether cardiomyocytes possess a self-protective or homeostatic mechanism that mitigates adverse myocardial remodeling.
RATIONALE: Junctophilin-2 (JP2) is a structural protein that organizes the E-C coupling ultrastructural machinery in cardiomyocytes. We previously showed that calpain-mediated proteolytic cleavage of JP2 is key to its downregulation in the diseased heart after cardiac stress. This cleavage contributes to loss of ultrastructural integrity at cardiac dyads, E-C uncoupling, and dysfunction of Ca 2+ handling that results in heart failure. Computational analyses predicted that JP2 contains a nuclear localization signal (NLS), as well as an alanine-rich region (ARR) with characteristics of a helix-turn-helix structure, a DNA binding motif. We tested the hypothesis that JP2 encodes a stress-adaptive transcriptional regulator, which transduces mechanical information (E-C uncoupling) into transcriptional reprogramming in the myocardium in the setting of cardiac stress.
RESULTS: Biochemical, mutagenesis, and confocal imaging analyses revealed that stress-induced proteolysis of JP2 liberated an N-terminal fragment (JP2NT) that was imported into the nucleus through its NLS. Further biochemical and microarray assays showed that in the nucleus, JP2NT associated with chromatin and regulated transcription of a wide spectrum of genes via an evolutionarily conserved ARR located in the a-helix region of JP2. Chromatin immunoprecipitation sequencing (ChIP-seq) of JP2NT-overexpressing hearts revealed that it bound preferentially to the transcription start sites (TSSs) of genes, and gel shift studies defined the DNA binding motifs of JP2NT as the TATA box and a MEF2-response element (MRE). Elevation of JP2NT levels by JP2NT overexpression altered the in vivo genomic binding profile of TATA-box binding protein (TBP) and MEF2C. In addition, JP2NT suppressed the transcriptional activity of MEF2C by competing for MRE. Overexpression of JP2NT in mice led to reprogramming of the transcriptome in the setting of stress and attenuated hypertrophic remodeling and the progression of heart failure. Loss of JP2NT function by deletion of the JP2 NLS in mice accelerated the development of hypertrophy and heart failure after cardiac stress.
CONCLUSION: Our data reveal that calpainmediated cleavage of JP2 transforms this E-C coupling structural protein into a transcriptional regulator that is shuttled into the nucleus and binds to promoters of target genes, inducing cardioprotective transcriptional reprogramming. These data reveal that cardiomyocytes possess a self-protective mechanism that counters pathological transcriptional remodeling after cardiac stress. Our findings also identify an intrinsic direct connection between ultrastructural remodeling and transcriptional reprogramming in the stressed heart.
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Normal Condition Stressed Condition
Schematic depiction of the mechanism by which JP2NT converts a mechanical stress signal to transcriptional reprogramming in the stressed heart. Left: E-C coupling under physiological conditions. Right: E-C coupling under pathologic conditions. Cardiac stress results in Ca 2+ overload (1), promoting calpain activation (2) . The resulting cleavage of JP2 liberates JP2NT from the T-tubule/sarcoplasmic reticulum junction, disrupting the ultrastructure of the E-C coupling machinery (3). JP2NT is shuttled into the nucleus via a conserved NLS (4) . JP2NT binds to TATA-box elements via the ARR and associates with a MEF2 response element (MRE) to repress the transcription of genes that control deleterious cardiac remodeling (5). , Long-Sheng Song 1,6,7 † Junctophilin-2 (JP2) is a structural protein required for normal excitation-contraction (E-C) coupling. After cardiac stress, JP2 is cleaved by the calcium ion-dependent protease calpain, which disrupts the E-C coupling ultrastructural machinery and drives heart failure progression. We found that stress-induced proteolysis of JP2 liberates an N-terminal fragment (JP2NT) that translocates to the nucleus, binds to genomic DNA, and controls expression of a spectrum of genes in cardiomyocytes. Transgenic overexpression of JP2NT in mice modifies the transcriptional profile, resulting in attenuated pathological remodeling in response to cardiac stress. Conversely, loss of nuclear JP2NT function accelerates stress-induced development of hypertrophy and heart failure in mutant mice. These data reveal a self-protective mechanism in failing cardiomyocytes that transduce mechanical information (E-C uncoupling) into salutary transcriptional reprogramming in the stressed heart.
C alcium ion (Ca
2+
) signaling affects almost every aspect of cells (1) . In heart muscle, excitation-contraction (E-C) coupling is a cascade of Ca 2+ -mediated processes linking membrane depolarization to activation of cell contraction (2) . At the cellular level, E-C coupling in working ventricular myocytes depends on precise communication between voltage-gated L-type Ca 2+ channels located mainly on the transverse tubule (T-tubule) membrane and Ca 2+ -sensitive ryanodine receptors (RyRs) on the terminal cisternae of the sarcoplasmic reticulum (SR) (3) (4) (5) (6) influx activates myofilaments, resulting in myocyte contraction. This intermolecular Ca 2+ crosstalk between L-type Ca 2+ channels and RyRs takes place in a confined spatial microdomain, where T-tubules and terminal cisternae of SR form tight junctional couplings with a gap of 12 to 15 nm, termed "cardiac dyads" (7) . Cardiac dyads provide the structural basis for E-C coupling and are established and maintained by junctophilin-2 (JP2) (8) . JP2 contains eight N-terminal MORN (membrane occupation and recognition nexus) domains that mediate interactions with the T-tubule membrane, a spacespanning a helix that is thought to control the dyad distance, and a C-terminal transmembrane (TM) domain that anchors JP2 in the SR membrane (8, 9) . Genetic manipulation of JP2 by silencing, knockout, or overexpression authenticated its role as a structural protein responsible for the formation of cardiac dyads and maintenance of normal E-C coupling in the heart (8, 10, 11) .
Defective E-C coupling is a hallmark of heart failure (12) (13) (14) (15) (16) . Recent studies have provided compelling evidence that the expression level of JP2 is decreased in failing hearts of multiple etiologies including human heart failure, contributing to the loss of ultrastructural integrity of cardiac dyads and E-C coupling dysfunction (16) (17) (18) (19) (20) (21) (22) . In particular, we discovered that JP2 proteolytic cleavage by calpain in response to cardiac stress represents a key mechanism of JP2 down-regulation, causing E-C uncoupling, Ca 2+ mishandling, and heart failure (23) (24) (25) . Abnormal Ca 2+ homeostasis triggers maladaptive transcriptional remodeling, contributing to pathological myocardial remodeling and development of heart failure (26) (27) (28) (29) (30) (31) (32) . However, it was not clear whether cardiomyocytes undergoing E-C uncoupling possess a self-protective or homeostatic mechanism that mitigates adverse myocardial remodeling. It was also unknown whether there is an intrinsic connection between cardiac ultrastructural remodeling at E-C coupling junctions and transcriptional reprogramming in stressed hearts.
Here, we show a mechanism in which a JP2 fragment, generated during cardiac stress and a marker of E-C uncoupling, serves as a negative feedback mechanism to antagonize maladaptive cardiac remodeling. This fragment translocates to the nucleus and represses transcriptional reprogramming, in part through regulating a key muscle transcription factor, MEF2 (myocyte enhancer factor 2). Specifically, we found that the a-helix domain of JP2 contains an evolutionarily conserved DNA binding domain. Under stress conditions, proteolytic processing of JP2 by calpain converts it from a structural protein to a transcriptional regulator, indicating an intrinsic connection between cardiomyocyte ultrastructural remodeling and transcriptional reprogramming in the heart.
Nuclear localization of JP2NT
We previously reported that JP2 is a substrate of calpain (calpain 1) and identified the primary calpain proteolysis site in the C-terminal region of JP2 between residues Arg 565 and Thr 566 (24) . Calpain cleavage creates an N-terminal truncate (residues 1 to 565, termed JP2NT) that contains the plasma membrane-binding MORN motifs, and a C-terminal fragment containing the SR membrane-anchoring TM domain (Fig. 1A) . We performed Western blotting with an antibody to an internal epitope of JP2, which is not destroyed by calpain cleavage of JP2 ( fig. S1A ). Analysis of subcellular fractions of mouse myocardium established that endogenous JP2NT (75 kDa) is present and predominantly enriched in nuclear fractions (Fig. 1B and fig. S1 , B and C). Immunostainings of human and mouse myocardium sections using the same antibody also detected a JP2 product in nuclei ( fig. S2, arrows) . In contrast, an antibody to the C terminus of JP2 did not detect JP2 signals in the nucleus of myocardium sections ( fig. S2 ). JP2NT was markedly increased in myocardium from mice with cardiacspecific overexpression of calpain1 and enriched in the nuclear fraction (Fig. 1C) [for calpain1-OE mice, see (33) ]. In addition, treatment with micrococcal nuclease (MNASE), which cleaves DNA and releases chromatin-associated proteins, released JP2NT from the chromatin pellet (Fig. 1C) ; this result substantiates the nuclear localization of endogenous JP2NT in vivo and suggests that JP2NT is a chromatin-associated protein.
We hypothesized that pathological stresses that activate calpain (34) promote the generation and nuclear accumulation of JP2NT. Consistent with this notion, we found that both isoproterenol infusion ( Fig. 1D and figs. S1B and S2A) and myocardial infarction (Fig. 1E, fig. S1C , and fig.  S2 , B and C) increased the amount of JP2NT in nuclei of stressed hearts relative to (sham) controls. Under pressure overload stress, nuclear accumulation of JP2NT reached its peak at 2 to 3 weeks after transaortic banding (TAB) surgery (Fig. 1F) . Conversely, administration of the calpain inhibitor MDL-28170 significantly attenuated stress-induced elevation in nuclear JP2NT (Fig. 1 , D to F), further supporting the idea that calpain-mediated proteolysis of fulllength JP2 under cardiac stress results in accumulation of nuclear JP2NT.
These data led us to postulate that the posttranslational removal of JP2 C terminus is sufficient to promote JP2NT translocation into the nucleus. To recapitulate the process by which calpain-mediated proteolysis is associated with Guo Rapamycin 100 nM 1h JP2NT translocation, we adapted an inducible split tobacco etch virus protease (sTEVp) system (Fig. 1G, i) (35) . A TEVp substrate recognition sequence (TRS) was inserted into an enhanced green fluorescent protein-JP2 fusion in the primary calpain cleavage site (Arg 565 /Thr 566 ) (eGFP-JP2TRS; Fig. 1G, i) . At baseline in human embryonic kidney (HEK) 293T cells, eGFP-JP2TRS was localized at the cell membrane and an intracellular network-like structure that is likely the endoplasmic reticulum (Fig. 1G, ii) . In the absence of rapamycin, cotransfection of sTEVp did not affect eGFP-JP2TRS localization (Fig. 1G, iii) . In cells expressing sTEVp, rapamycin treatment rapidly induced nuclear importation of eGFP-JP2TRS N terminus (Fig. 1G, v) . These data show that JP2 C terminus anchors the intact JP2 protein at the dyad, and that removal of JP2 C terminus is sufficient to induce trafficking of the N-terminal fragment into nuclei.
JP2NT has a NLS and a chromatin/DNA binding region
To investigate the molecular mechanism of JP2NT nuclear importation, we performed in silico analysis (36) . In JP2NT, we found a monopartite Guo (Fig. 2A, iii and iv) and cardiomyocytes ( fig. S3E ), indicating that this NLS is indispensable for nuclear localization of JP2NT. A fusion protein containing mCherry and the bNLS peptide together with the ARR was imported into nuclei ( fig. S3D ). However, deletion of the bNLS sequence from JP2NT (eGFP-JP2NT DbNLS ) did not prevent its nuclear importation in HEK293T cells ( Fig. 2A, v) and cardiomyocytes ( fig. S3E ), indicating that this region is not necessary for nuclear importation of JP2NT. However, the subnuclear localization of eGFP-JP2NT
DbNLS was mutually exclusive from To-Pro-3 staining, which labels genomic DNA ( Fig. 2A, v) , suggesting physical dissociation of eGFP-JP2NT
DbNLS from genomic DNA.
Deletion of the adjacent ARR from JP2NT (eGFP-JP2NT DARR ) induced greater separation of eGFP-JP2NT from DNA and was accompanied by accumulation of DNA at the nuclear periphery ( Fig. 2A, vi) . These data indicate that bNLS and ARR are involved in DNA or chromatin binding.
To further confirm the association of JP2NT with chromatin, we applied a biochemical fractionation procedure (38) (Fig. 2B, i) . JP2NT was detected in both soluble (S3) and chromatincontaining insoluble (P4) nuclear fractions (Fig. 2B,  ii, a) . MNASE-mediated DNA digestion released JP2NT from the insoluble chromatin fraction (MNASE+/S4) (Fig. 2B, ii, a) ChIP-seq signal 
MORN domains from JP2NT (JP2NT
DMORNs
) did not influence its distribution in the nucleus or its association with chromatin (Fig. 2B, ii, b) . In contrast, deletion of the bNLS-like sequence from this construct (JP2NT DMORNs/DbNLS ) significantly reduced the association of JP2NT with chromatin (Fig. 2B, ii, c) . Deletion of the alaninerich domain in combination with the bNLS (JP2NT DMORNs/DbNLS/DARR or JP2NT DbNLS/DARR ) completely prevented presence of JP2NT in the MNASE-releasable chromatin fraction (Fig.  2B, ii, d to f) . On the basis of these data, we conclude that JP2NT associates with chromatin via a domain located at residues~345 to 402, which is highly evolutionarily conserved in mammalian species as well as in vertebrates such as fish and birds ( fig. S3C ).
JP2NT is enriched at transcription start sites
To systematically study the genomic targets of JP2NT, we generated transgenic mice with cardiacspecific overexpression of hemagglutinin (HA)-tagged JP2NT. In these mice, JP2NT is predominantly localized in the nuclei of cardiomyocytes (fig. S4A ). The level of JP2NT transgene in nuclear fraction is of the same order of magnitude, relative to the peak level of endogenous JP2NT induced by TAB (Fig. 1F) . Hearts of the JP2NT-overexpressing mice (JP2NT-OE) were subjected to chromatin immunoprecipitation sequencing (ChIP-seq) analysis using antibody to HA. Two replicates of ChIP-seq analyses were performed using different batches of JP2NT heart samples. Only the DNA peaks (P < 10 −10 ) that were detected in both replicates of ChIP-seq analyses were considered as JP2NT-binding DNA regions. We identified 9414 JP2NT-binding genomic DNA regions encompassing 7398 genes. The DNA binding profile revealed that JP2NT is concentrated in gene-enriched regions, especially the promoter and 5′ untranslated regions (Fig. 3A) . Moreover, JP2NT is preferentially enriched at transcription start sites (Fig. 3B) , a characteristic of transcription regulators. We 5 of 9 compared JP2NT occupancy of genomic loci with that of cardiac polymerase II (Pol II) and acetylated histone H3 Lys 9 (H3K9ac, a marker for active promoters and enhancers) binding peaks from published data (39). We found that 95% of JP2NT peaks overlap with H3K9ac peaks and 78% overlap with Pol II peaks ( Fig. 3C ; example tracks shown in fig. S4B, a) . These data strongly suggest that JP2NT regulates active cardiac transcription.
JP2NT is a TATA-box binding protein and interacts with transcription machinery
On the basis of these results, we hypothesized that JP2NT may directly associate with core cisregulatory elements that regulate transcription initiation. Cross-linking reversal coimmunoprecipitation experiments in JP2NT transgenic cardiomyocytes demonstrated that JP2NT associates with RNA Pol II (RPB1) and TATA-box binding protein (TBP), both of which are components of the basic transcriptional machinery ( fig. S5A ). TBP specifically binds to TATA boxes, eukaryotic core cis-regulatory elements localized at transcription start sites. Subsequent in vitro analysis with purified recombinant glutathione S-transferase (GST)-JP2NT revealed that JP2NT directly binds to the TATA box or variants (TATAAA, TATAAT, and TATATA) from the cMyc (Fig. 3D,  i, and fig. S5B ) or the CMV promoter ( fig. S5C ). This interaction was abrogated by mutation of the TATA-box elements (Fig. 3D, ii, and fig. S5B ). We conclude that JP2NT is a DNA binding protein, binding to the consensus TATA box represented as TATAA(A/T) or TATATA (Fig. 3D, iii) .
Deletion of N-terminal MORN domains alone from JP2NT (GST-JP2NT
DMORNs ) did not alter the interaction of JP2NT with the TATA-box oligonucleotide (Fig. 3D, iv, and fig. S5C ). However, deletion of the ARR from this construct (GST-JP2NT DMORNs/DARR ) completely abrogated the association of JP2NT with TATA-box elements (Fig. 3D, iv, and fig. S5C ). Conversely, a purified peptide containing the ARR (GST-JP2 331-405 ) specifically bound to the consensus but not the mutant TATA box (Fig. 3D, v, and fig. S5D ). Together, these data indicate that the ARR is responsible for TATA-box binding.
JP2NT modulates MEF2-mediated transcription via competing for MEF2 binding sites
The MEF2 family, master regulators of hypertrophic genes in cardiomyocytes, binds to the A/T enriched consensus sequence (C/T TA(A/T)4TA G/A), which shares the same core sequence with the TATA box. Thus, we hypothesized that JP2NT directly interacts with the MEF2 response element (MRE). Consistent with this hypothesis, MEF2 binding motifs were significantly enriched in the ChIP-seq dataset (Fig. 4A and table S1 ). Gel shift assay demonstrated that purified JP2NT or purified DNA binding domain of JP2NT (GST-JP2 ) interacts with a MRE from the desmin enhancer (Fig. 4B and fig. S6A ). The specificity of this interaction was further shown by mutant MRE oligos (Fig. 4B ) and cold competitor assay ( fig. S6B ). Biotinylated oligo DNA pull-down assay confirmed that the JP2NT transgene as well as endogenous full-length JP2 from heart lysis can interact with MRE ( fig. S6C ). Coimmunoprecipitation of HEK293T cells transfected with Myc-tagged MEF2C and HA-tagged JP2NT demonstrated an interaction of the two proteins (Fig. 4C) . The interaction of endogenous MEF2C with JP2NT transgene was confirmed in JP2NT transgenic hearts (Fig. 4C) .
To examine whether JP2NT regulates MEF2-mediated transcription, we used a luciferase reporter system with firefly cDNA driven by desmin enhancer-derived MRE (P MEF2 -firefly) (40) . Cotransfection of a plasmid expressing MEF2C and P MEF2 -firefly in HEK293T cells significantly increased the firefly luciferase signal relative to constitutive P SV40 -renilla (Fig. 4, D and E) . Cotransfection of JP2NT attenuated the MEF2-responsive signal in a dose-dependent manner (Fig. 4D) . By contrast, MEF2C-mediated transcriptional activity was not significantly altered in cells expressing a JP2NT construct lacking the ARR (JP2NT DARR , Fig. 4E ), which we found to be required for its association with chromatin and TATA box sequences. These data suggest that JP2NT competes with MEF2 for direct interaction with its consensus sequence at promoters to block MEF2-mediated transcription.
JP2NT alters DNA binding profiles of TBP and MEF2C in cardiomyocytes
To understand whether JP2NT influences DNA occupancy of MEF2 in cardiomyocytes, we analyzed the DNA binding profile of MEF2C in control and JP2NT-OE myocardium. ChIP-seq analyses revealed that JP2NT-OE suppressed MEF2C interactions at 42% of the endogenous MEF2C binding sites. JP2NT-OE created 2386 new MEF2C binding peaks that are absent in control hearts, and 65% of them overlap with JP2NT binding sites. In addition, 33% of the MEF2C binding peaks inhibited by JP2NT-OE overlap with JP2NT binding sites (Fig. 4F) . ChIPseq analyses of TBP revealed that~25% of the endogenous TBP binding sites were suppressed by JP2NT-OE, and 22% of them overlap with JP2NT binding sites. JP2NT-OE created 2192 new TBP binding peaks, and 28% of them overlap with JP2NT binding sites ( Fig. 4F ; example tracks shown in fig. S4B, b to e) . These data indicate that JP2NT can affect MEF2C and TBP DNA binding, either by competing for the endogenous binding sites or by recruiting MEF2C and TBP to new binding sites.
Overexpression of JP2NT in cultured cardiomyocytes induces profound changes in transcriptional profile
The association of JP2NT with DNA and transcription machinery led us to investigate whether JP2NT directly modulates the transcriptional profile in cardiomyocytes. Compared with cardiomyocytes infected with empty adenovirus (Ad-Empty control), Affymetrix GeneChip analysis revealed that the expression of 574 and 1996 known genes were significantly induced or repressed (P < 0.01), respectively, in JP2NT-expressing cardiomyocytes (Fig. 5A and fig.  S7A ; see table S2 for complete list of differentially expressed genes). Conversely, only 96 significantly induced and 264 significantly repressed genes were detected in cardiomyocytes with overexpression of full-length JP2 (Fig. 5A and  fig. S7B ). Of the differentially expressed genes induced by JP2NT,~60% mapped to genomic loci where JP2NT was found to bind by ChIP-seq; this proportion is significantly larger than thẽ 46% (P < 10
) of JP2NT binding genes among those genes whose expression was detectable in cardiomyocytes but was not significantly influenced by JP2NT. Notably, the regulatory effect of JP2NT on gene expression appeared to be dependent on binding of JP2NT to gene loci: Among the differentially expressed genes for which JP2NT bound to the genomic loci, the vast majority (84%) were down-regulated in the presence of JP2NT overexpression; this percentage is decreased to 67% (P < 10
) in differentially expressed genes not bound by JP2NT. We interpret these findings to indicate that JP2NT represses transcription by binding to genomic regions, either directly through binding to TATA box and MRE or through interactions with transcription factors such as MEF2C and TBP.
Many of the JP2NT-down-regulated genes encode nuclear proteins ( fig. S7C ) and proteins that are functionally enriched in nuclear events such as transcriptional regulation and chromatin modification ( fig. S7D ). Ingenuity Pathway Analysis (IPA; Qiagen) of the differentially expressed genes induced by JP2NT identified pathways and regulators implicated in cardiac hypertrophy, fibrosis, cell growth, and differentiation as well as inflammation. Specifically, ERK/MAPK, NF-kB, TGF-b, and integrin signaling pathways were predicted to be inhibited in response to JP2NT overexpression ( Fig. 5B and table S3 ). Confirming these GeneChip findings, reverse transcription quantitative polymerase chain reaction (RT-qPCR) revealed that mRNA levels of genes including those that encode KLF4, KLF6, Myc, TGFbR1, NFKBIA, FOXO1, and PI3KR1 were significantly decreased in cardiomyocytes expressing JP2NT relative to Ad-Empty infected cells (Fig. 5C) . Deletion of the DNA binding region from JP2NT (JP2NT DbNLS/DARR ) largely prevented the repressive effect of JP2NT (Fig. 5C) . Notably, the cardiac hypertrophy markers ANP and BNP were not altered by JP2NT expression but were significantly increased by JP2NT DbNLS/DARR (Fig. 5C) .
To further test whether JP2NT regulates transcription of these genes, we constructed luciferase reporters controlled by promoters of Myc, KLF6, TGFbR1, and NFKBIA. For all genes, promoter activity was significantly attenuated by coexpression of JP2NT in HEK293T cells (Fig.  5D) . Consistent with the changes in mRNA levels, expression of JP2NT DbNLS/DARR either had no effect on baseline firefly luciferase signal or increased promoter activity as compared to empty vector control (Fig. 5D) , supporting the idea that the DNA binding domain of JP2NT is important for its function as a transcriptional repressor.
JP2NT attenuates hypertrophic response and heart failure development in mice Because JP2NT represses transcription of key regulators of hypertrophy, fibrosis, and inflammation, we predicted that JP2NT would exert a protective effect on stress-induced pathological cardiac remodeling. At baseline, JP2NT overexpression had no effect on cardiac morphology or function (Fig. 6, A to C) . The E-C coupling function at the single-cell level (e.g., L-type Ca 2+ channel densities, amplitude and kinetics of Ca 2+ transients, SR Ca 2+ content, and the gain function of E-C coupling) was not altered by the JP2NT transgene ( fig. S8 ). Under stress conditions induced by TAB surgery to produce pressure overload hypertrophy and heart failure, JP2NT-OE mice had improved cardiac function (Fig. 6A) , lower heart weight/body weight ratio (Fig. 6B) , and reduced lung edema indicated by the lung weight/body weight ratio (Fig. 6C) relative to controls. These results suggest that JP2NT-OE protects the heart against stress-induced pathological remodeling.
RNA-seq demonstrated minor differences in the cardiac transcription profile of JP2NT-OE mice at baseline relative to control littermates ( fig. S9A) , with only 220 significantly altered genes (P < 0.01). TAB promoted a marked change in the transcriptome of control hearts as compared to sham surgery, with 4636 significantly altered transcripts derived from 3580 genes ( fig. S8B ). Overexpression of JP2NT significantly modified the transcriptional response to cardiac stress: We detected a significant difference in 1082 transcripts derived from 954 known genes based on a linear regression model (P < 0.01, Fig. 6D ). Among these, 540 transcripts (mapped to 481 known genes) were negatively influenced and 542 transcripts (mapped to 476 known genes) positively influenced by JP2NT overexpression (see table S4), with a predicted inhibition of ERK, TGF-b, CREB, and NF-kB signaling pathways (Fig. 6E and table S5 ). These findings are in line with observations in cultured cardiomyocytes (Fig. 5B) and substantiate a pivotal role for JP2NT in the cardiac response to stress by inhibiting transcriptional reprogramming. handling function compared to wild-type littermates under baseline condition (Fig. 6, F to I,  and fig. S10 , C to E). However, when subjected to TAB, JP2 DNLS -KI mice developed more severe cardiac hypertrophy and worsened heart function relative to wild-type littermates. Three weeks after TAB, echocardiography detected larger myocardium mass (Fig. 6F) , higher end diastolic volume (EDV) (Fig. 6H) and end systolic volume (ESV) (Fig. 6I) , and lower ejection fraction (Fig. 6G ) in JP2 DNLS -KI mice than in wild-type littermates. These findings suggest that JP2NT functions as an endogenous cardiac protector against pathological challenges.
Discussion
Our study provides compelling evidence suggesting that an E-C coupling structural protein can also act as a transcriptional regulator. We have shown that regulated cleavage of JP2 converts it from a structural protein to a nuclear transcriptional regulator via an NLS and an ARR contained within JP2NT. JP2NT is enriched in the promoter region of genes in cardiomyocytes and primarily acts as a transcriptional repressor of genes implicated in cell growth and differentiation, hypertrophy, inflammation, and fibrosis, with evidence for a specific interaction with the transcription factor MEF2. Cardiac-specific transgenic overexpression of JP2NT attenuates pressure overload induced development of heart failure, identifying JP2NT generation as a selfprotective homeostatic mechanism that safeguards against the deleterious effects of cardiac stress. These discoveries reveal a signaling pathway that transduces membrane stresses into transcriptome changes in the setting of E-C uncoupling after cardiac stress.
JP2 was initially discovered as a structural protein with dual membrane-anchoring domains Guo that connect T-tubules and the SR membrane (8) .
Here, we discovered that JP2 contains additional regulatory domains that extend beyond its role as a structural protein. An NLS in the N-terminal region of JP2 is necessary for nuclear import of the calpain-generated JP2NT truncate. Thus, under stress conditions, calpain-mediated cleavage of JP2 serves two purposes: (i) It impairs the bridging of T-tubules with the SR membrane [contributing to cardiomyocyte ultrastructural remodeling and E-C uncoupling (23)], and (ii) it liberates JP2NT, allowing JP2NT to translocate to the nucleus and mediate transcriptional reprogramming. In addition, we found that the a-helix region of JP2 contains a previously unappreciated DNA binding domain that mediates selective binding to canonical TATA box motifs and MRE. This DNA binding domain is evolutionarily conserved, suggestive of a dual function for JP2 as a structural protein and transcriptional regulator in other species. The development and progression of heart failure involves diverse cellular and molecular mechanisms (41, 42) . Our ChIP-seq and transcriptomic profiling data suggest that JP2NT suppresses gene transcription by targeting multiple signaling pathways such as inflammatory responses, fibrosis, myocyte hypotrophy, and cell death among others. Taken with the protective effect of JP2NT overexpression in the setting of cardiac stress, this study indicates that JP2NT is an endogenous self-protective stress transducer that conveys the E-C uncoupling signal to the nucleus, regulates transcriptional reprogramming, and ultimately attenuates the progression of heart failure. As JP2 is abundant in all muscle cells (cardiac, skeletal, and smooth muscle), JP2NT may serve as a general protective mechanism antagonizing stress-induced pathological remodeling related to many diseases.
